Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men

Obesity is associated with low testosterone in men and with dyslipidemia. Adropin hormone is negatively correlated with body mass index and is associated with dyslipidemia.

correlation between adropin and testosterone will be evaluated.

Study Overview

• Status: Completed
• Conditions: Obesity; Dyslipidemias
• Intervention / Treatment: Diagnostic test: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL)); Diagnostic test: Total testosterone; Diagnostic test: Adropin; Diagnostic test: Adiponectin

Detailed Description

Obesity, a worldwide epidemic is associated with multiple adverse health outcome as diabetes mellitus, hypertension and cardiovascular diseases caused mainly by dyslipidemia linked to obesity. Low testosterone levels in obese men were found associated with dyslipidemia.

Adropin is a new metabolic hormone that was first isolated in liver and brain tissues, It was observed that mice fed on a high-fat diet (HFD) had a rapid increase in adropin expression compared to control values. In human also, adropin levels were negatively correlated with body mass index (BMI) and were associated with dyslipidemia.

Adiponectin is a protein that is mainly produced by white adipose tissue and has an important role in lipid metabolism. Serum adiponectin concentrations were decreased in obese compared to normal weight men and significantly correlated with testosterone level.

• Study Type: Observational
• Enrollment (Actual): 82

Contacts and Locations

Study Locations

• Egypt
  • Aswan, Egypt, 81528
    • Aswan University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

• Sampling Method: Non-Probability Sample

Study Population

obese and normal weight men from 18 years to 50 years

Description

Inclusion Criteria:

Age from 18 years to 50 years. Clinically free except from obesity

Exclusion Criteria:

• Diabetes mellitus Hypertension Heart failure Kidney disease Smoking

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
obese men; Adult obese men (BMI ≥ 30 kg/m2)	Diagnostic test: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL)); blood samples will be collected after 10 hours fasting; Diagnostic test: Total testosterone; blood samples will be collected after 10 hours fasting; Diagnostic test: Adropin; blood samples will be collected after 10 hours fasting; Diagnostic test: Adiponectin; blood samples will be collected after 10 hours fasting
normal men; normal weight men (18.5 ≤ BMI < 25 kg/m2 )	Diagnostic test: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL)); blood samples will be collected after 10 hours fasting; Diagnostic test: Total testosterone; blood samples will be collected after 10 hours fasting; Diagnostic test: Adropin; blood samples will be collected after 10 hours fasting; Diagnostic test: Adiponectin; blood samples will be collected after 10 hours fasting

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
changes in lipid profile (TC, TG, LDL, HDL) levels	expected higher TC, TG, LDl levels and lower HDL levels in obese men compared to normal	6 months
changes in total testosterone levels	expected lower testosterone levels in obese men compared to normal men	6 months
changes in adropin level	expected lower adropin levels in obese men compared to normal men	6 months
changed in adiponectin levels	expected lower adiponectin level in obese men compared to normal men	6 months
correlation between adropin and testosterone		6 months
correlation between adropin and adiponectin		6 months

Collaborators and Investigators

• Sponsor: Aswan University Hospital
• Investigators: Principal Investigator: Asmaa Abdelmageed Muhammed, Assistant lecturer, Aswan University Hospital

Publications and helpful links

General Publications

• Canguven O, Talib RA, El Ansari W, Yassin DJ, Salman M, Al-Ansari A. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men. Andrologia. 2017 Dec;49(10). doi: 10.1111/and.12768. Epub 2017 Mar 10.
• Ghoshal S, Stevens JR, Billon C, Girardet C, Sitaula S, Leon AS, Rao DC, Skinner JS, Rankinen T, Bouchard C, Nunez MV, Stanhope KL, Howatt DA, Daugherty A, Zhang J, Schuelke M, Weiss EP, Coffey AR, Bennett BJ, Sethupathy P, Burris TP, Havel PJ, Butler AA. Adropin: An endocrine link between the biological clock and cholesterol homeostasis. Mol Metab. 2018 Feb;8:51-64. doi: 10.1016/j.molmet.2017.12.002. Epub 2017 Dec 30.
• Yosaee S, Khodadost M, Esteghamati A, Speakman JR, Shidfar F, Nazari MN, Bitarafan V, Djafarian K. Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects. Am J Mens Health. 2017 Mar;11(2):426-434. doi: 10.1177/1557988316664074. Epub 2016 Aug 22.
• Kim AY, Park YJ, Pan X, Shin KC, Kwak SH, Bassas AF, Sallam RM, Park KS, Alfadda AA, Xu A, Kim JB. Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance. Nat Commun. 2015 Jul 3;6:7585. doi: 10.1038/ncomms8585.
• Thomas S, Kratzsch D, Schaab M, Scholz M, Grunewald S, Thiery J, Paasch U, Kratzsch J. Seminal plasma adipokine levels are correlated with functional characteristics of spermatozoa. Fertil Steril. 2013 Apr;99(5):1256-1263.e3. doi: 10.1016/j.fertnstert.2012.12.022. Epub 2013 Jan 30.
• Muhammed AA, Eid RMHM, Mohammed WS, Abdel-Fadeil MR. An association between adropin hormone and total testosterone in obese men: a case-control study. BMC Endocr Disord. 2022 Jul 27;22(1):192. doi: 10.1186/s12902-022-01102-7.

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2018
• Primary Completion (Actual): November 29, 2019
• Study Completion (Actual): January 7, 2020

Study Registration Dates

• First Submitted: October 29, 2018
• First Submitted That Met QC Criteria: October 29, 2018
• First Posted (Actual): October 30, 2018

Study Record Updates

• Last Update Posted (Actual): March 2, 2022
• Last Update Submitted That Met QC Criteria: February 14, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: testosterone; obese men; adiponectin; Adropin
• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Dyslipidemias; Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Androgens; Testosterone
• Other Study ID Numbers: Adropin in obese men

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No